Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:10:43.132Z.
Calculation as of: 2026-10-06T18:10:43.132Z.
Quote observation: 2026-10-06T18:08:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b909c1583fef9061a4d716d1bfa7e8c39158eca830282836b9decd9e758125
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Akanda Corp.
Market Cap
$60871.00
EV/FCF Ratio
N/A
Market Cap
$30509.00
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Akanda Corp. (AKAN) | $60871.00 | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $72519.00 | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30509.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $96236.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109567.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6153.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $245816.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $384448.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
